Ibiayi Dagogo-Jack

Ibiayi Dagogo-Jack

UNVERIFIED PROFILE

Are you Ibiayi Dagogo-Jack?   Register this Author

Register author
Ibiayi Dagogo-Jack

Ibiayi Dagogo-Jack

Publications by authors named "Ibiayi Dagogo-Jack"

Are you Ibiayi Dagogo-Jack?   Register this Author

40Publications

1651Reads

45Profile Views

Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.

J Thorac Oncol 2020 Jan 24. Epub 2020 Jan 24.

Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.01.002DOI Listing
January 2020

Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity.

Clin Cancer Res 2019 Nov 29;25(22):6662-6670. Epub 2019 Jul 29.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858956PMC
November 2019

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

J Thorac Oncol 2019 Oct;14(10):e226-e228

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.05.046DOI Listing
October 2019

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.

J Thorac Oncol 2019 05 18;14(5):835-843. Epub 2019 Jan 18.

Massachusetts General Hospital, Center for Integrated Diagnostics, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.032DOI Listing
May 2019

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

J Thorac Oncol 2019 05 18;14(5):816-824. Epub 2019 Jan 18.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486857PMC
May 2019

BRAF Mutation Class and Clinical Outcomes-Response.

Clin Cancer Res 2019 05;25(10):3189

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0422DOI Listing
May 2019

Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.

Lung Cancer 2019 03 16;129:80-84. Epub 2019 Jan 16.

Department of Radiology, Massachusetts General Hospital, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002193002
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2019.01.007DOI Listing
March 2019

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

Pharmacol Ther 2019 01 16;193:20-30. Epub 2018 Aug 16.

Massachusetts General Hospital Cancer Center, Charlestown, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2018.08.007DOI Listing
January 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Clin Cancer Res 2019 01 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

J Thorac Oncol 2018 11;13(11):e226-e227

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183077
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.06.021DOI Listing
November 2018

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Lung Cancer 2018 08 22;122:67-71. Epub 2018 May 22.

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062851PMC
August 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Tumour heterogeneity and resistance to cancer therapies.

Nat Rev Clin Oncol 2018 02 8;15(2):81-94. Epub 2017 Nov 8.

Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 7B, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.166DOI Listing
February 2018

Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

Am Soc Clin Oncol Educ Book 2017 ;37:619-629

From the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hematology/Oncology Fellowship Program, Moffitt Cancer Center, Tampa, FL; University of South Florida, Tampa, FL; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175197DOI Listing
November 2017

Expanding the Roster of ROS1 Inhibitors.

J Clin Oncol 2017 08 18;35(23):2595-2597. Epub 2017 May 18.

Ibiayi Dagogo-Jack and Alice T. Shaw, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2586DOI Listing
August 2017

The Role of Liquid Biopsies in Lung Cancer Screening.

Semin Roentgenol 2017 Jul 3;52(3):185-187. Epub 2017 Jun 3.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ro.2017.06.001DOI Listing
July 2017

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

J Immunother 2017 04;40(3):108-113

*Massachusetts General Hospital Cancer Center †Department of Radiology, Massachusetts General Hospital, Harvard Medical School ‡Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000159DOI Listing
April 2017

Treatment of brain metastases in the modern genomic era.

Pharmacol Ther 2017 02 20;170:64-72. Epub 2016 Oct 20.

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2016.10.011DOI Listing
February 2017

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

J Thorac Oncol 2016 09 11;11(9):1522-8. Epub 2016 Jun 11.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002360PMC
September 2016

Brain Metastasis: Clinical Implications of Branched Evolution.

Trends Cancer 2016 07 29;2(7):332-337. Epub 2016 Jun 29.

Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Cancer Program, The Eli and Edythe L. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA; Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.06.005DOI Listing
July 2016

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Oncologist 2016 06 31;21(6):662-3. Epub 2016 May 31.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912373PMC
June 2016

The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT.

J Natl Compr Canc Netw 2015 Feb;13(2):184-9

From the Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, and Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0027DOI Listing
February 2015

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Clin Cancer Res 2014 Mar 27;20(5):1135-45. Epub 2013 Nov 27.

Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts; Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France; Hematology Laboratory, University Hospital; and INSERM U892, Nantes, France; Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts; Biotique Systems Inc., www.biotiquesystems.com; Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458245PMC
March 2014

That which we carry with us.

Pharos Alpha Omega Alpha Honor Med Soc 2011 ;74(2):34-6

University of Chicago Pritzker School of Medicine, USA.

View Article

Download full-text PDF

Source
June 2011